Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.
Palmer AJ; Mount Hood 5 Modeling Group; Clarke P, Gray A, Leal J, Lloyd A, Grant D, Palmer J, Foos V, Lamotte M, Hermann W, Barhak J, Willis M, Coleman R, Zhang P, McEwan P, Betz Brown J, Gerdtham U, Huang E, Briggs A, Carlsson KS, Valentine W. Palmer AJ, et al. Among authors: coleman r. Value Health. 2013 Jun;16(4):670-85. doi: 10.1016/j.jval.2013.01.002. Epub 2013 Apr 18. Value Health. 2013. PMID: 23796302 Free article.
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group. Zoungas S, et al. Among authors: coleman rl. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30. Lancet Diabetes Endocrinol. 2017. PMID: 28365411
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Morrow LM, Becker F, Coleman RL, Gerstein HC, Rydén L, Schöder S, Gray AM, Leal J, Holman RR; ACE Study Group. Morrow LM, et al. Among authors: coleman rl. J Diabetes. 2024 Feb;16(2):e13473. doi: 10.1111/1753-0407.13473. Epub 2023 Nov 1. J Diabetes. 2024. PMID: 37915263 Free PMC article. Clinical Trial.
Microvascular outcomes in type 2 diabetes - Authors' reply.
Zoungas S, Gerstein HC, Holman RR, Reaven P, Woodward M, Arima H, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) writing group. Zoungas S, et al. Among authors: coleman rl. Lancet Diabetes Endocrinol. 2017 Aug;5(8):580. doi: 10.1016/S2213-8587(17)30185-7. Lancet Diabetes Endocrinol. 2017. PMID: 28732664 No abstract available.
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group. Holman RR, et al. Among authors: coleman rl. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917545 Free article. Clinical Trial.
3,517 results